Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05025085 | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | PHASE1 | COMPLETED | 25 | — | — | Oct 4, 2021 | Apr 1, 2024 | Oct 15, 2025 | 11 | United States |
| Arm | Type | Description |
|---|---|---|
| Monotherapy with AGEN1777 | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days \[3 weeks\]). |
| AGEN1777 in combination with a PD-1 inhibitor | EXPERIMENTAL | 3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days. |
| Name | Type | Description |
|---|---|---|
| AGEN1777 | DRUG | An immunoglobulin gamma (IgG1) antibody |
| a PD-1 inhibitor | DRUG | Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumor for which no acceptable standard therapy available or progressed on or after standard therapies. 2. Measurable disease on baseline imaging based on Response Evaluation Criter...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |